Clinical trials: Nausea
Gastroparesis
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
The purpose of this research is to determine if temporary gastric electrical stimulation will help improve symptoms of gastroparesis (abnormal stomach emptying).
- Trial name
- NCT00432835
- Testing
- Gastric Electrical Stimulator, Enterra, Medtronics, Inc.
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of Mississippi Medical Center
Chemotherapy-Induced Nausea and Vomiting, Ovarian Cancer
Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin
The current recommended guideline for patients receiving moderately emetogenic chemotherapy (MEC) is the combination of a 5-HT3 receptor antagonist and corticosteroid.
- Trial name
- NCT01012336
- Testing
- Aprepitant/Ramosetron/Dexamethasone
- Where
- South Korea
- Volunteers
- 89 people
- Sponsor
- Samsung Medical Center
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic…
- Trial name
- NCT01031498
- Testing
- Ondansetron, Palonosetron
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Osteoarthritis, Knee
Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty
The purposes of this study are to document the antiemetic efficacy of multimodal antiemetic protocol in patient after Total Knee Arthroplasty using regional anesthesia, midazolam \& propofol, hydration \& oxygen supplement…
- Trial name
- NCT01102491
- Testing
- Ramosetron
- Where
- South Korea
- Volunteers
- 153 people
- Sponsor
- Seoul National University Hospital
Melanoma
Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
Primary Objectives: Safety of palonosetron administered for control of nausea and vomiting in patients with metastatic melanoma receiving biochemotherapy.
- Trial name
- NCT00412425
- Testing
- Palonosetron
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Postoperative Nausea and Vomiting
Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy
The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.
- Trial name
- NCT00888329
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Mayo Clinic
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Postoperative Nausea and Vomiting
Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV.
- Trial name
- NCT00895830
- Testing
- APD405
- Where
- 18 sites in United States, France and 2 more
- Volunteers
- 257 people
- Sponsor
- Acacia Pharma Ltd
Gastroparesis
Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)
This study is to evaluate the safety and effectiveness of gastric stimulation in the reduction of nausea and vomiting in patients with gastroparesis using an approved Humanitarian device.
- Trial name
- NCT00157755
- Testing
- Enterra Therapy
- Where
- 6 sites in United States
- Volunteers
- 87 people
- Sponsor
- MedtronicNeuro